Data Support Lowering Age for CRC Screening to 45 Years
For those aged 45 to 49 years, 32 percent had any neoplasia, 7.5 percent had advanced premalignant lesions, 0.58 percent had CRC
Colorectal And Other GI Cancers
Maintenance of Clinical Remission Observed With Mirikizumab in UC Trial
LUCENT-2 is a maintenance study evaluating the efficacy and safety of mirikizumab in patients who achieved clinical response in the 12-week LUCENT-1 induction study.
Colorectal Cancer Screening Should Start at Age 45 Years
Recommendation based on increasing disease burden in those younger than 50 years, modeling studies demonstrating benefits outweighing harms, costs of screening
Clinical Remission, Endoscopic Response Seen With Upadacitinib in Crohn Disease Trial
Over 60% of the study participants had previously failed 2 or more biologic therapies.
FDA Rejects Pedmark NDA Again Citing Manufacturing Deficiencies
The application could not be approved in its present form due to manufacturing deficiencies.
Sulfur Microbial Diet May Increase Risk for Colorectal Cancer
Sulfur microbial diet features high intakes of low-calorie drinks, red meats, processed meats and low intakes of fruits, vegetables, whole grains
Rivoceranib Designated Orphan Drug for Hepatocellular Carcinoma
Rivoceranib is an orally administered, small molecule inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2).
Novel Multikinase Inhibitor Gets Fast Track Status for Cholangiocarcinoma
The designation is based on results from a phase 1 study that evaluated TT-00420 at different dose levels in 9 CCA patients.
Erbitux Plus Encorafenib Approved for BRAF V600E Mutation-Positive Metastatic Colorectal Cancer
The approval is supported by data from the phase 3 BEACON CRC trial in adults with BRAF V600E mutation-positive metastatic colorectal cancer with disease progression.
AbbVie Seeks Approval of Risankizumab for Crohn Disease
The application is supported by data from two phase 3 induction studies (ADVANCE and MOTIVATE) and one phase 3 maintenance study (FORTIFY).
